The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Targeting the complement system for the management of retinal inflammatory and degenerative diseases
Open accessAbstract
The retina, an immune privileged tissue, has specialized immune defense mechanisms against noxious insults that may exist in diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), uveoretinitis and glaucoma. The defense system consists of retinal innate immune cells (including microglia, perivascular macrophages, and a small population of dendritic cells) and the complement system. Under normal aging conditions, retinal innate immune cells and the complement system undergo a low-grade activation (parainflammation) which is important for retinal homeostasis. In disease states such as AMD and DR, the parainflammatory response is dysregulated and develops into detrimental chronic inflammation. Complement activation in the retina is an important part of chronic inflammation and may contribute to retinal pathology in these disease states. Here, we review the evidence that supports the role of uncontrolled or dysregulated complement activation in various retinal degenerative and angiogenic conditions. We also discuss current strategies that are used to develop complement-based therapies for retinal diseases such as AMD. The potential benefits of complement inhibition in DR, uveoretinitis and glaucoma are also discussed, as well as the need for further research to better understand the mechanisms of complement-mediated retinal damage in these disease states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 2×
“A low-level of tissue insult may initiate a protective para-inflammation (Chovatiya and Medzhitov, 2014; Medzhitov, 2008).”
BackgroundRother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 2×
“Eculizumab, another C5 speci fi c mAb, had been approved for the treatment of PNH and atypical hemolytic uremic syndrome (aHUS) (Rother et al., 2007).”
BackgroundAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
Stress, Inflammation, and Defense of Homeostasis
Chovatiya, R., & Medzhitov, R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.030 · Cited by 704
Para-Inflammation in the Aging Retina
Xu, H., Chen, M., & Forrester, J. V. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.001 · Cited by 659 · cited 1×
“The retina contains at least three types of innate immune cells: microglia, perivascular macrophages, and dendritic cells (DCs) (Forrester et al., 2010; Xu et al., 2009).”
BackgroundSelf-citationDrusen complement components C3a and C5a promote choroidal neovascularization
Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408835103 · Cited by 650
Kazama, H., Ricci, J.-E., Herndon, J. M., Hoppe, G., Green, D. R., & Ferguson, T. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.013 · Cited by 627 · cited 1×
“Mechanisms to induce the death of in fi ltrating immune cells through Fas ligand (FasL) and Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) pathways also exist in the retina (Ferguson and Grif fi th, 1997; Ferguson and Grif fi th, 2007; Kazama et al., 2008).”
BackgroundCombadière, C., Feumi, C., Raoul, W., Keller, N., Rodéro, M., Pézard, A., Lavalette, S., Houssier, M., Jonet, L., Picard, E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31692 · Cited by 618 · cited 3×
“Examples of the immune modulatory mechanisms include (but are not limited to) the CD200-CD200R (Dick et al., 2003) and CX3CL1-CX3CR1 (Combadiere et al., 2007) pathway, thrombospondin-1, TGF-β , CTLA4, CTLA2, and various complement inhibitors (Horie et al., 2010; Kawazoe et al., 2012; Mochizuki et al., 2013; Sugita et…”
BackgroundHowell, G. R., Macalinao, D. G., Sousa, G. L., Walden, M., Soto, I., Kneeland, S. C., Barbay, J. M., King, B. L., Marchant, J. K., Hibbs, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44646 · Cited by 473
The proinflammatory mediators C3a and C5a are essential for liver regeneration
Strey, C. W., Markiewski, M., Mastellos, D., Tudoran, R., Spruce, L. A., Greenbaum, L. E., & Lambris, J. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030374 · Cited by 436 · cited 2×
“In addition to their proinflammatory properties, C3a and C5a also participate in tissue regeneration and fibrosis (Hillebrandt et al., 2005; Strey et al., 2003).”
BackgroundParainflammation, Chronic Inflammation and Age-Related Macular Degeneration
Chen, M., & Xu, H. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0615-239r · Cited by 381
Self-citationHeier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304 · cited 1×
“The disease is treated by intravitreal injection of VEGF inhibitors (e.g., Avastin, Lucentis s , Eyelea) (Heier et al., 2006; Holz et al., 2014; Kodjikian et al., 2014).”
BackgroundYehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Microglia in the healthy and degenerating retina: Insights from novel mouse models
Karlstetter, M., Ebert, S., & Langmann, T. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.05.010 · Cited by 197 · cited 1×
“The role of retinal microglia in retinal health and disease has been reviewed extensively else-where (Karlstetter et al., 2010; Karlstetter et al., 2015; Langmann, 2007; Li et al., 2015).”
BackgroundDendritic cell physiology and function in the eye
Forrester, J. V., Xu, H., Kuffová, L., Dick, A. D., & McMenamin, P. G. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00873.x · Cited by 195 · cited 2×
“The BRB also sequesters retinal antigens within the intraocular compartment avoiding T cell activation, a phenomenon called immunological ignorance (Avichezer et al., 2003; Forrester et al., 2008; Forrester et al., 2010; Forrester and Xu, 2012).”
BackgroundSelf-citationImmunoregulatory mechanisms of the eye
Streilein, J. W., Wilbanks, G. A., & Cousins, S. W. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90253-h · Cited by 157 · cited 1×
“Thirdly, the retina has a sophisticated immune regulatory system orchestrated by retinal cells, including various neurons and RPE cells (Streilein, 1999; Streilein et al., 2002; Wenkel and Streilein, 2000).”
BackgroundThrombospondin Plays a Vital Role in the Immune Privilege of the Eye
Zamiri, P., Masli, S., Kitaichi, N., Taylor, A. W., & Streilein, J. W. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0362 · Cited by 143
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142 · cited 1×
“However, the data about whether polymorphisms in complement genes and other AMD risk factor genes can be used to predict the response to VEGFA ‑ targeted therapies are con fl icting (Hagstrom et al., 2013, Smailhodzic et al., 2012).”
BackgroundImmune Activation in Retinal Aging: A Gene Expression Study
Chen, M., Muckersie, E., Forrester, J. V., & Xu, H. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-5103 · Cited by 130
Self-citationChen, H., Liu, B., Lukas, T. J., & Neufeld, A. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002339 · Cited by 129 · cited 5×
“Compelling evidence suggests that a complement regulatory system exists in the retina-RPE/choroid.”
BackgroundInfluentialDick, A. D., Ford, A. L., Forrester, J. V., & Sedgwick, J. D. (1995) · British Journal of Ophthalmology · doi:10.1136/bjo.79.9.834 · Cited by 129 · cited 2×
“CD11b and F4/80, the former expresses high levels of CD14 (LPS receptor) and CD45, whereas microglia are CD14CD45 (Dick et al., 1995; Fischer and Reichmann, 2001; Tavazzi et al., 2014).”
BackgroundThe microglia in healthy and diseased retina
Li, L., Eter, N., & Heiduschka, P. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.04.020 · Cited by 112
Chen, M., Muckersie, E., Robertson, M., Forrester, J. V., & Xu, H. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.09.005 · Cited by 99 · cited 5×
“Compelling evidence suggests that a complement regulatory system exists in the retina-RPE/choroid.”
BackgroundInfluentialSelf-citationLueck, K., Wasmuth, S., Williams, J., Hughes, T. R., Morgan, B. P., Lommatzsch, A., Greenwood, J., Moss, S. E., & Pauleikhoff, D. (2011) · Eye · doi:10.1038/eye.2011.109 · Cited by 80
Vogt, S. D., Barnum, S. R., Curcio, C. A., & Read, R. W. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.04.002 · Cited by 71
Gregerson, D. S., & Yang, J. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1014 · Cited by 55 · cited 1×
“Using fl ow cytometry analysis, Gre-gerson and Yang detected a small population of CD11c þ DEC205 þ DCs in normal mouse retina (Gregerson and Yang, 2003).”
MethodBora, N. S., Jha, P., Lyzogubov, V. V., Kaliappan, S., Liu, J., Tytarenko, R. G., Fraser, D. A., Morgan, B. P., & Bora, P. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153130 · Cited by 53 · cited 6×
“, 2013), or administration of the complement regulatory molecules CD59 (Bora et al., 2010) and CFH (Kim et al.”
BackgroundInfluential
Cited by
Inflammation in Glaucoma: From the back to the front of the eye, and beyond
Baudouin, C., Kolko, M., Melik-Parsadaniantz, S., & Messmer, E. M. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100916 · Cited by 454
Microglia in the Retina: Roles in Development, Maturity, and Disease
Silverman, S. M., & Wong, W. T. (2018) · Annual Review of Vision Science · doi:10.1146/annurev-vision-091517-034425 · Cited by 346
Immune Regulation in the Aging Retina
Chen, M., Luo, C., Zhao, J., Devarajan, G., & Xu, H. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.10.003 · Cited by 305
Self-citationA new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
“Work on the complement system in AMD pathogenesis has received significant attention and that work in recent years has been translated to explorations on the use of complement inhibitors in human clinical trials on AMD (Geerlings et al., 2017; Williams et al., 2014; Xu and Chen, 2016).”
BackgroundPatel, S. S., Lally, D. R., Hsu, J., Wykoff, C. C., Eichenbaum, D., Heier, J. S., Jaffe, G. J., Westby, K., Desai, D., Zhu, L., et al. (2023) · Eye · doi:10.1038/s41433-023-02497-w · Cited by 147
“Evidence suggests a role of the complement pathway in AMD and GA, and the potential for complement system components as therapeutic targets [5 – 7].”
Background
Metadata
- Authors
- Xu, H., & Chen, M.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 787
- Pages
- 94-104
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2290011308
- Cited by
- 160
- References
- 27
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.